Enter inventor name

Ivan Tarasovich Gout

USPTO Granted Patents = 13 (Patent Applications = 2)

Average Co-Inventor Count = 7.1

ph-index = 4

Forward Citations = 135(Granted Patents)

Company Filing History:

13 out of 525

Ludwig Institute for Cancer Research Limited

patents

4 out of 560

Memorial Sloan Kettering Cancer Center

patents

3 out of 3

Institute of Molecular Biology and Genetics National Academy of Science of Ukraine

patents

4. 1 out of 512

Sloan-kettering Institute for Cancer Research

patents

5. 1 out of 1

Institute for Molecular Biology and Genetics National Academy of Science of Ukraine

where one patent can have more than one assignee

Years Active: 1998-2019

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10385138 - Antibodies directed to membrane transporter NaP12b (SLC34A2) and uses thereof in cancer therapy (2019-08-20),

2. 9701755 - Membrane transporter NaPi2b (SCL34A2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy (2017-07-11),

3. 9045533 - Membrane transporter NaPi2b (SCL34A2) epitope antibodies (2015-06-02),

4. 8669347 - Truncated variant of the mammalian target for rapamycin (MTOR) protein (2014-03-11),

5. 8603474 - Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy (2013-12-10),

6. 7998718 - Identification and functional characterization of a novel ribosomal S6 protein kinase (2011-08-16),

7. 7422849 - Method for determining expression of a PI3 kinase gene (2008-09-09),

8. 7335467 - Breast cancer antigens (2008-02-26),

9. 6830909 - Identification and functional characterization of a novel ribosomal S6 protein kinase (2004-12-14),

10. 6274327 - Polypeptides having kinase activity, their preparation and use (2001-08-14),

11. 5846824 - Polypeptides having kinase activity, their preparation and use (1998-12-08),

12. 5824492 - Polypeptides having kinase activity, their preparation and use (1998-10-20),

13. 5741689 - Methods to inhibit serine kinase activity and to alter intersubunit (1998-04-21),

Title: Ivan Tarasovich Gout: Innovator in Cancer Therapy

Introduction

Ivan Tarasovich Gout is an accomplished inventor based in London, GB, known for his significant contributions to the field of cancer therapy. With a remarkable portfolio of 13 patents, Gout has focused on harnessing the power of immunotherapy to target cancerous cells effectively.

Latest Patents

His latest patents include innovative discoveries related to antibodies directed to the membrane transporter NaPi2b (SLC34A2). This invention highlights SLC34A2 as a target for immunotherapy, particularly in the context of ovarian cancer treatment. Gout’s research has identified an epitope peptide of SLC34A2, which has been shown to elicit an immune response against tumors. His inventions also encompass the development of various forms of antibodies, including veneered, chimeric, single chain, and humanized antibodies, aimed at treating cancer and enhancing immunological responses.

Career Highlights

Throughout his career, Ivan Tarasovich Gout has made significant strides in cancer research. He has worked with prestigious organizations such as the Ludwig Institute for Cancer Research Limited and Memorial Sloan Kettering Cancer Center, where he contributed to groundbreaking research in cancer therapies and treatments.

Collaborations

Gout has collaborated with notable scientists, including Michael Derek Waterfield and Ian D Hiles. These collaborations have enhanced his research and have been instrumental in advancing the field of cancer therapy through innovative approaches.

Conclusion

Ivan Tarasovich Gout's contributions to cancer therapy illustrate his dedication to improving patient outcomes through scientific innovation. His work on antibodies targeting SLC34A2 not only reflects his inventive spirit but also his commitment to combating cancer with cutting-edge therapeutic strategies. With 13 patents to his name, Gout continues to be a pivotal figure in the realm of medical research and innovation.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com